if you've read the body keeps the score — this room's founding book — you know bessel van der kolk's forty-year argument: talk alone often can't reach where trauma lives. so it mattered when he became a principal investigator in the most watched trauma experiment in decades: mdma-assisted therapy for ptsd. the model isn't recreational use — it's the drug given a handful of times, inside long, therapist-supported sessions, to open a window in which the hardest material can finally be approached. as he has argued for decades, trauma is not just an event in your past — it's the imprint that experience leaves on mind, brain, and body.
the trial results looked remarkable. in the pivotal phase 3 study, a majority of participants — people with severe, long-standing ptsd — improved dramatically; in a sub-study van der kolk co-led, the treated group showed significantly greater gains in self-compassion, the thing trauma strips first. by 2024, approval looked close to inevitable. in august 2024, the fda said no.
why the no was real
this site tells it straight, and the honest version is that the rejection wasn't bureaucrats fearing a stigmatized drug. the fda's objections were substantive. the biggest is almost funny until you see the problem: mdma's effects are unmistakable, so nearly everyone in the trials — patients and therapists — could tell who got the real drug. the "blind" in double-blind was broken from the start, and when people know they got the breakthrough treatment, expectation itself becomes a medicine you can't subtract from the results. add to that: three published papers from the program were retracted that same month over serious ethics violations at one trial site, and the agency had unanswered questions about how long the benefits last. any one of those might have been survivable. together, they sank it.
a promising medicine and a flawed application are two different things — and the honest version of this story holds both.
where it stands now
the aftermath was brutal — the sponsoring company cut most of its staff and rebuilt under a new name — but the story didn't end. in 2026 the fda finalized new rules for psychedelic trials that directly address the blinding problem, which is regulator language for: show us this properly and we'll look again. the field's own founders still expect approval to come, in years rather than months.
so, plainly, for anyone carrying trauma and watching these headlines with hope: mdma-assisted therapy is not an approved treatment today, and the unauthorized version — a powerful drug without the screening, the setting, or the trained support that the actual protocol is built on — is not the thing the trials tested, and not safe to seek out. what is available now is everything this room already teaches: the body-based approaches, the slow completion work, and a real person across a real table. the possible medicine of the future is not a reason to skip the real help of the present. van der kolk himself has spent forty years saying the healing agent was never only the molecule — it's the safety in the room. that part was never waiting on the fda.